- $8.94m
- -$4.16m
- $3.03m
Brief: Neurometrix Reports Q4 And Full Year 2021 Financial Results
U.S. STOCKS ON THE MOVE-Ford, Splash Beverage, semiconductor stocks, U.S. Bancorp
U.S. STOCKS ON THE MOVE-Gaming stocks, Kohl's, U.S. airlines
NeuroMetrix soars on breakthrough device tag for neurostimulator
NASDAQ RESUMED AT 09:50 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:37 AM
Brief: NeuroMetrix Receives FDA Breakthrough Device Designation For Treatment Of Chronic Chemotherapy Induced Peripheral Neuropathy
Brief: NeuroMetrix Inc Enters Into Sales Agreement Under Which Company May Offer And Sell Shares Of Up To $25 Million
Brief: Neurometrix Inc Files For Mixed Shelf Of Upto $50 Million
Brief: Neurometrix Posts Q3 Revenue $2.1 Million
NeuroMetrix jumps on FDA application for fibromyalgia device
NASDAQ RESUMED AT 10:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:02 AM
U.S. STOCKS ON THE MOVE-Alibaba, Gap, Apple, Workday
Brief: NeuroMetrix Announces Peer-Reviewed Publication Of Controlled Trial Of Wearable Neurostimulation Technology
U.S. STOCKS ON THE MOVE-Sequential Brands, Summit Wireless, Seres Therapeutics
U.S. STOCKS ON THE MOVE-Seres Therapeutics, TRACON Pharmaceuticals, NeuroMetrix
U.S. STOCKS ON THE MOVE-Crocs, NeuroMetrix, Seres Therapeutics
Brief: NeuroMetrix Q2 Revenue Rose 63%